mTOR Inhibition Overcomes RSK3-mediated Resistance to BET Inhibitors in Small Cell Lung Cancer

Anju Kumari¹, Lisa Gesumaria¹, Yan-Jin Liu¹, V. Keith Hughitt², Xiaohu Zhang³, Michele Ceribelli³, Kelli M. Wilson³, Carleen Klumpp-Thomas³, Lu Chen³, Crystal McKnight³, Zina Itkin³, Craig J. Thomas^{3,4,◇}, Beverly A. Mock^{2,◇}, David S. Schrump^{1,◇}, Haobin Chen^{1,*}

¹Thoracic Surgery Branch, ²Laboratory of Cancer Biology and Genetics, ⁴Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

³Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

◇ Senior authors.

*** Corresponding author:**

Haobin Chen, 10 Center Drive Room 3-5888, National Institutes of Health, Bethesda, MD 20892
Tel: 240-760-6177; Fax: 240-541-4584; Email: haobin.chen@nih.gov

Running title: Combination of mTOR and BET inhibitors in SCLC

Keywords: Apoptosis; Drug combination; High-throughput screens; Signaling

Funding: This study was supported by a FLEX award from the Center for Cancer Research, the Intramural Program of the National Cancer Institute (NCI) (BC011839: Chen, Mock, Schrump, and Thomas), and in part by the NCI Intramural Research Program (BC011787: Chen) and the Division of Preclinical Innovation, National Center for Advancing Translational Sciences.

Conflict of interest statement: The authors declare no potential conflicts of interest.

Manuscript word count: 4,913; Number of figures: 6; Number of tables: 0

Abstract

Purpose: SCLC is a recalcitrant malignancy with limited treatment options. BET inhibitors have shown promising preclinical activity in SCLC, but their broad sensitivity spectrum limits their clinical prospects in this malignancy. Drug combination could be a solution.

Experimental design: We performed high-throughput drug combination screens in SCLC cell lines to identify potential therapeutics synergizing with BET inhibitors. Validation was performed in SCLC cell lines and patient-derived xenograft models. Genome-wide RNA sequencing of xenograft tumors was performed to determine the mechanism underlying the synergy of the drug combination.

Results: Inhibitors of the PI-3K-AKT-mTOR pathway were the top candidates from the screens. Among the therapeutics targeting this pathway, mTOR inhibitors showed the highest degree of synergy with BET inhibitors *in vitro*. Furthermore, the combination of these two classes of drugs showed superior antitumor efficacy and tolerability *in vivo*. Using both *in vitro* and *in vivo* SCLC models, we demonstrate that BET inhibitors activate the intrinsic apoptotic cascade, and mTOR inhibitors further enhance these apoptotic effects. Mechanistically, BET inhibitors activate the TSC2-mTOR-p70S6K1 signaling cascade by upregulating RSK3, an upstream kinase of TSC2. Activation of p70S6K1 leads to BAD phosphorylation and cell survival. mTOR inhibition blocks this survival signaling cascade and potentiates the antitumor effects of BET inhibitors.

Conclusions: Our results demonstrate that RSK3 upregulation is a novel resistance mechanism of BET inhibitors in SCLC, and mTOR inhibition can overcome this resistance and enhance apoptosis. These findings provide a rationale to evaluate the combination of mTOR and BET inhibitors in patients with SCLC.

Introduction

Small cell lung cancer (SCLC) is a recalcitrant malignancy with limited treatment options (1). Recent analysis of the Surveillance, Epidemiology, and End Results data found no improvement in the 2-year survival rates of this malignancy from 2001 to 2014 because of limited treatment advances (2). Several new therapeutics, including immune checkpoint inhibitors and lurbinectedin, have been recently approved by the FDA for SCLC, but only a subset of patients receives benefits (3). Therefore, there is an unmet need to develop novel therapies for SCLC.

A potential therapeutic candidate for SCLC is BET inhibitor (BETi). This class of drugs targets the bromodomain and extra-terminal domain (BET) family proteins, namely BRD2, BRD3, BRD4, and BRDT. The primary function of the BET family proteins is gene transcription regulation, and the two bromodomains in each of these proteins are critical for this function by enabling access to active chromatin. BETi binds to these bromodomains and dissociates the BET family proteins from active chromatin, resulting in the suppression of gene transcription. Because BETi only suppresses a subset of genes - particularly those related to cell lineage and driver oncogenes (4), there has been considerable interest in applying this class of drugs for cancer treatment.

A study in preclinical mouse models suggested that SCLC cells are exquisitely susceptible to BETi (5), but a subsequent investigation revealed a broad sensitivity range among human SCLC lines (6). There have been several efforts in developing drug combinations to enhance the antitumoral effects of BETi and to delay the onset of drug resistance. For instance, inhibitors targeting PARP, HDAC6, or BCL2 were found to synergize with BETi in SCLC (7-10). However, to our knowledge, an unbiased screen among the existing oncological therapeutics in combination

with BETi has not been reported in SCLC. In addition, the mechanisms underlying BETi resistance are not fully understood in this malignancy.

The PI-3K-AKT-mTOR pathway is commonly activated in cancer, and a recent study identified mTOR as an essential kinase in a subset of SCLC through shRNA library screens (11). Currently, everolimus (an mTOR inhibitor [mTORi]) has been approved for the treatment of multiple neoplasms. However, a phase II trial of everolimus in an unselected patient population of relapsed SCLC only found limited single-agent antitumor activity, suggesting a need to combine this drug with other therapeutics (12). Interestingly, in breast and prostate cancer cell lines, inhibition of mTOR complex 1 (mTORC1) caused a feedback activation of receptor tyrosine kinases (RTKs), which led to phosphorylation at AKT T308 and activation of its downstream signaling to promote survival (13,14). BETi was reported to potentiate the antitumor effects of mTORi by blocking the upregulation of RTKs and thus decreasing this feedback activation in breast and colon cancer cell lines (15,16). To our knowledge, the combination of mTORi and BETi has not been studied in SCLC.

In this study, we performed high-throughput drug combination screens to identify potential therapeutics synergizing with BETi in SCLC in an unbiased manner.

Materials and Methods

Cell Culture. H446, H187, H460, H1048, H1436, Calu-6, MDA-MB-468, and HEK293T cells were purchased from the American Type Culture Collection, SCLC-21H was from the German Collection of Microorganisms and Cell Cultures, and COR-L279 and COR-L88 were from Sigma. LX95 SCLC line was established by growing the single cells isolated from the LX95 PDX tumors in HITES medium (DMEM:F12 medium supplemented with 0.005mg/ml insulin, 0.01 mg/ml

transferrin, 30 nM sodium selenite, 10 nM hydrocortisone, 10 nM beta-estradiol, 1x Glutamax, 5% heat-inactivated fetal bovine serum, 1x penicillin/streptomycin). H446 cells with ectopic expression of BCL2 were established by transfection of H446 cells with Flag-BCL2 (a gift from Clark Distelhorst (17); Addgene plasmid #18003) followed by selection with 0.4 mg/ml G418 (Roche). All cell lines were grown in culture media recommended by the suppliers and were maintained in humidified incubators at 37°C. MDA-MB-468 was grown at 100% air, while all other lines were at 5% CO₂. All cell lines tested negative for mycoplasma, and short tandem repeat analysis was performed to authenticate commercial cell lines.

Reagents. For *in vitro* studies, (±)-JQ1 (Sigma, #SML0974), NHWD870 (a gift from Nenghui Wang and Mingzhu Yin, Ningbo Wenda Pharma), actinomycin D (Sigma, #A9415), everolimus (Sellekchem, #S1120), LJH685 (Sellekchem, #S7870), MK-2206 (Sellekchem, #S1078), PF-4708671 (Sellekchem, #S2163), rapamycin (Sellekchem, #S1039), torkinib (Sellekchem, #S2218), and Z-VAD-FMK (Sigma, # 219007) were dissolved in DMSO; copanlisib (Sellekchem, #S2802) was prepared in 10% trifluoroacetic acid (Sigma, #T6508).

For *in vivo* studies, AZD5153 (Chemitek, #CT-A5153), AZD5363 (Chemitek, #CT-A5363) and NHWD870 were first dissolved in N,N-dimethylacetamide (Sigma, #270555) and then mixed with 0.5% methylcellulose (Sigma, #M0430) plus 0.1% Tween-80 (Sigma, #P4780) before administration. Everolimus was first dissolved in propylene glycol (Sigma, # W294004) at 10mg/600μl concentration and was then combined with 1ml 10% Tween 80, and finally with 400μl water. After mixing, the drug solution was mixed with 0.5% methylcellulose plus 0.1% Tween-80 prior to each dosing.

High-Throughput Combinatorial Screens. High-throughput combinatorial screens were performed as previously described (18) with some modifications. The initial screen was performed

in H446 cells by combining JQ1 with each drug from a Mechanism Interrogation PlatE (MIPE) 4.0 library in a 6x6 matrix layout. The MIPE 4.0 library consists of 1,912 FDA-approved oncological therapeutics and investigational agents. The viability endpoint of the initial screen was measured using the CellTiterGlo® reagent (Promega) 72 hours after drug treatment. The synergy of various drug combinations was assessed using the excess Highest Single Agent (HSA) method, the response heat map, and the Δ Bliss heat map (19,20).

The second screen was performed in four SCLC cell lines (H446, COR-L279, H187, and SCLC-21H) in a 10x10 matrix by combining JQ1 or iBET-762 with one of the 40 drugs selected from the first screen. The endpoints of the second screen were caspase 3/7 activity measured using the CaspaseGlo® 3/7 assay reagent (Promega) at the 8-hour and 16-hour time intervals, as well as cell viability measured using the CellTiterGlo® reagent at the 72-hour time interval following drug treatment.

Cell Viability and Caspase 3/7 Activity Assay. Cells were dissociated with TrypLE (ThermoFisher), and large cell clumps were removed by passing the cell solution through sterile 40 μ m nylon mesh cell strainers (Fisher Scientific, Hampton, NH). Subsequently, 750 cells in 15 μ l growth media were seeded into each well of a 384-well plate (Corning, #3765). On the next day, drugs were serially diluted 2-fold in appropriate solvents to generate nine consecutive concentrations. Then, the compound and its vehicle control were diluted 100 times in culture media and delivered to the cells in 10% of the final volume to achieve a total of 1,000X dilution. Assays were performed with four replicates for each dose. Caspase 3/7 activity was measured using the caspase-glo® 3/7 Assay system (Promega) 48 hours after drug treatment, and cell viability was

examined at the 72-hour interval using the CellTiter-Glo® 2.0 Reagent (Promega). A reflective foil seal (Bio-Rad, #MSF1001) was applied to the bottom of each plate to maximize the output signal.

Transfection. Lipofectamine 2000 or 3000 reagents (ThermoFisher) were used for lipofection by following the manufacturer's recommendations. The Myr-RSK3 vector (pWZL Neo Myr Flag RPS6KA2) was a kind gift from William Hahn & Jean Zhao (Addgene plasmid # 20621; (21)).

Western Blot Analysis. After cells were collected and washed with PBS, cells were lysed in cold 1X RIPA lysis buffer (Millipore) supplemented with a protease inhibitor cocktail (Sigma). When a phosphorylated protein was measured, RIPA lysis buffer was also complemented with a phosphatase inhibitor cocktail (Sigma or ThermoFisher). After incubation on ice for 10 minutes, cells were centrifuged at 10,000 g for 10 minutes to extract cell lysates. Mitochondrial fractions (for cytochrome c measurement) and membrane fractions (for Myr-RSK3 measurement) were extracted from cells using a Cell Fractionation kit (Abcam) and a Mem-PER™ Plus Membrane Protein Extraction Kit (ThermoFisher), respectively.

Proteins were quantified using a Pierce BCA Protein Assay Kit (ThermoFisher). Equivalent amounts of protein were resolved on precast polyacrylamide denaturing gels and were then transferred onto 0.2 µm PVDF membranes using either dry transfer with an iBLOT2 system (ThermoFisher) or conventional wet transfer. Membranes were incubated with primary antibodies at the concentrations specified in Table S1. After membrane incubation with an appropriate secondary antibody, the presence of a protein of interest was detected by chemical fluorescence following a conventional ECL Western blotting protocol. Densitometry analysis was performed using the Image Lab software (Biorad).

Animal Studies. The animal experiments were approved and performed according to the regulations set by the National Cancer Institute-Bethesda Animal Care and Use Committee. SCLC patient-derived xenograft (PDX) LX33 and LX95 models were generously provided by Charles M. Rudin and John T. Poirier (22,23). Freshly isolated PDX tumors were dissociated into single-cell suspensions using the Human Tumor Dissociation Kit (Miltenyi Biotec) and a gentleMACS™ Octo Dissociator (Miltenyi Biotec) following the manufacturer's instructions. After washing cells with PBS three times, red blood cells were lysed by resuspending cells in 5 ml ACK lysis buffer (Quality Biological) followed by incubation at room temperature for 5 minutes. After another three washes with PBS, approximately 5×10^6 viable cells in 100 μ l PBS were injected subcutaneously into the right flanks of 6-week-old NOD-SCID mice (Charles River Laboratories).

Once the tumor volume reached 50-100 mm³ (average, 14-21 days), mice were randomized into each treatment group and were given vehicle, NHWD870 or AZD5153, everolimus or AZD5363, or a combination of two drugs via oral gavage. The dosages and frequencies of drug administration are specified in the figure legends. Body weights and tumor sizes were measured every three days. Treatment was on hold if one of the following two criteria was met: 1) >15% body weight loss compared to the initial body weight (at the point of randomization); or 2) active diarrhea. Treatment was resumed once the bodyweight loss recovered to <10% reduction of the initial weight and diarrhea had stopped for three days. Animals were euthanized if 1) tumor volume was ≥ 1500 mm³; 2) tumor became ulcerated; 3) 75 days had elapsed after a tumor became palpable.

Histology Analysis. Formalin-fixed tumors were embedded in paraffin wax, and sectioned tissues were stained with hematoxylin and eosin or with anti-cleaved caspase 3 (Cell Signaling

Technology, #4850, 1:200) and anti-RSK3 antibodies (Novus Biologicals, NBP2-52555, 1:200). Quantification of cleaved caspase 3-positive cells was performed using QuPath [v0.2.2; (24)] by counting cytoplasmic staining-positive cells in 4-15 randomly selected images of each tumor.

RNA Isolation from Tumor Cell of PDX. Tumor cells were isolated from PDX using a magnetic-activated cell sorting method (25). In brief, after obtaining single-cell suspensions from fresh tumors, cells were centrifuged and resuspended at concentrations of 2×10^6 cells per 80 μ l PBS supplemented with 0.5% bovine serum albumin (Sigma). Afterward, cells were mixed with a 20 μ l cocktail from a Mouse Cell Depletion Kit (Miltenyi Biotec). Separation of mouse cells from human tumor cells was achieved using an LS column on a MACS Separator (Miltenyi Biotec). The flow-through fraction, which contained enriched human tumor cells, was collected by centrifugation. The cell pellet was processed for total RNA isolation using an RNeasy Mini Kit (Qiagen).

RNA Sequencing (RNA-seq). mRNA libraries were constructed using a TruSeq Stranded mRNA Library Prep kit V2 (Illumina) and were paired-end sequenced on a HiSeq 4000 system (Illumina) at the NCI Frederick Sequencing core facility.

RNA-seq reads were processed using the Snakemake-based ladb-wf transcriptomics pipeline v1.3c (<https://github.com/ladb/ladb-wf>) (26). Briefly, quality was assessed using FastQ Screen and FastQC, and adapter sequences and low-quality base pairs were trimmed using cutadapt. Trimmed reads were then mapped to the human reference genome (encode v30) using HISAT2 (v2.1.0), and transcript levels were quantified using the *featureCounts* method from RSubRead (v1.6.4). Differential expression analysis was performed in the R/Bioconductor

environment (R v4.0.2; Bioconductor v2.48.0) using the DESeq2 package (v1.28.0) (27,28). After constructing a DESeqDataSet object from the read counts generated by RSubRead, generalized linear models were fit with default parameters using a treatment coding design (e.g., NHWD870 vs. Vehicle). Finally, shrunken log-fold changes were estimated for each contrast using the *apeglm* adaptive t prior shrinkage approach (29).

Quantitative Reverse-transcription PCR (RT-PCR) Assay. After total RNA isolation, RNA was quantified using Nanodrop. Equivalent amounts of total RNA were used for cDNA synthesis using an iScript cDNA Synthesis kit (Bio-Rad). Quantitative analysis of *RPS6KA2* was performed using a SsoAdvanced™ Universal SYBR® Green Supermix (Biorad) and a set of specific primers (*RPS6KA2*, Biorad, qHsaCED0042305; β -actin, Biorad, qHsaCED0036269) on an ABI PRISM7500 real-time PCR system (ThermoFisher).

Data Analysis and Statistical Analysis. GraphPad Prism 8.0 was used for statistical analysis and graphing. CompuSyn (www.combosyn.com) was used to determine drug synergy of the low-throughput experiments by calculating combination indexes (30). Two-sample comparisons were performed using the Student's unpaired *t*-test, and multiple sample comparisons were analyzed using the ANOVA test with multiple comparison correction (Dunnett's method). The Log-rank (Mantel-Cox) test was employed for Kaplan-Meier survival analyses. A two-tailed $p < 0.05$ was considered statistically significant. Error bars represent mean $\pm$ SD.

Data Availability. All screen results are publicly accessible at <https://tripod.nih.gov/matrix-client/>. RNA-seq raw data were deposited in the GEO database (GSE155923).

Results

mTORi synergizes with BETi *in vitro*

We first examined the combination of JQ1 (a prototype BETi) and a MIPE 4.0 library of 1,912 approved and investigational drugs, using a 6×6 matrix layout and an endpoint of cell viability. The outcomes of this experiment demonstrated a strong enrichment for mTORi agents (e.g., rapamycin, everolimus, ridaforolimus, and temsirolimus) among the highest-ranked synergetic drug-drug pairs (Fig. 1a and Table S2).

Follow-up studies explored 40 of the most promising outcomes using an expanded 10×10 matrix layout with optimized concentration ranges. JQ1 and another BETi, I-BET762, were tested in parallel across 4 SCLC cell lines (H446, COR-L279, H187, and SCLC-21H). Besides cell viability at 72 hours after treatment, we also measured apoptosis induction at the 8- and 16-hour time intervals. Figure 1b shows a typical example of drug synergy heatmaps. We identified 22 drugs synergistic with JQ1 and I-BET762 in 3 or 4 out of the 4 SCLC cell lines, with inhibitors targeting the PI-3K-AKT-mTOR pathway being on the top of the list (Fig. 1c).

To validate the results of the high-throughput screens, we performed independent viability assays using a fixed concentration ratio of two-drug combinations. As shown in one typical example in Figure 1d, concurrent treatment with rapamycin decreased the IC₅₀ value of JQ1 by 10-fold in COR-L279 cells. We quantified the synergy between JQ1 and the inhibitors targeting PI-3K (copanlisib), AKT (MK-2206), or mTOR (rapamycin) using the method of Chou and Talalay (30). On the basis of the combination index (CI) at four different dose levels that caused a 50%, 75%, 90%, and 95% decrease in cell viability (fraction affected), the combination of JQ1 and rapamycin showed a higher degree of synergy than the other two combinations in COR-L279, H446, and H187 cells (Figs. 1e and S1a). Because the toxicity profiles of mTORi and BETi are

non-overlapping and their combination shows the highest degree of synergy, we focused on this combination for subsequent study.

To ensure the synergy between rapamycin and JQ1 was not due to an off-target effect, we evaluated the combinations of JQ1 and various mTORi agents (first generation: rapamycin and everolimus; second-generation: torkinib), as well as the cotreatment of everolimus and a different BETi (NHWD870; (31)). As shown in Figure S1b, the combinations of various mTOR and BET inhibitors consistently demonstrated a strong synergy. We also tested the combination of JQ1 and everolimus in SCLC cell lines resistant to JQ1 ($IC_{50} \geq 20\mu M$), and a strong synergy was observed in 2 out of 3 cell lines (Fig. S1c). Collectively, these results demonstrate that mTORi potentiates the growth inhibitory effects of BETi in SCLC lines.

mTOR inhibition amplifies BETi-induced apoptosis in SCLC

We next asked whether the combinations of mTORi and BETi induce apoptosis in SCLC. To answer this, we treated COR-L279 cells with the combination of JQ1 and rapamycin in the presence or absence of a pan-caspase inhibitor, Z-VAD-FMK. As shown in Figure 2a, Z-VAD-FMK drastically attenuated the decrease in cell viability caused by the JQ1 and rapamycin combo, suggesting that apoptosis is partly responsible for growth inhibition. Apoptosis can be triggered through either the intrinsic or extrinsic cascade, with the former one characterized by cleavage of caspase 9 and the latter by cleavage of caspase 8 (Fig. 2b). Both pathways converge on the cleavage of caspase 3 and PARP to activate cell death, and crosstalk between these two pathways can occur through cleaved BID (also known as t-BID).

To dissect which apoptotic pathway is activated by the mTORi and BETi combo, we first examined cleaved caspase 9, a key intermediate of the intrinsic cascade. As shown in Figure 2c,

JQ1 increased cleaved caspase 9 and the downstream cleaved caspase 3 and PARP; the addition of everolimus further increased these cleaved apoptotic proteins, suggesting that JQ1 and the combo activated the intrinsic apoptotic pathway. Because the intrinsic apoptotic cascade is typically triggered by the release of cytochrome c from mitochondria (Fig. 2b), we isolated cytosolic and mitochondrial fractions of COR-L279 cells after drug treatments. As shown in Figure 2d, cytochrome c was elevated in the cytosolic fraction of the JQ1-treated cells and was substantially higher in the sample treated with the everolimus and JQ1 combination, providing further evidence of involvement of the intrinsic apoptotic pathway. To further confirm that the intrinsic pathway is activated, we utilized an H446 cell line stably expressing ectopic BCL2, an antiapoptotic protein that stabilizes mitochondrial membrane and blocks the efflux of cytochrome c (Fig. 2e). The JQ1 and rapamycin combination was less effective in suppressing the growth of cells with ectopic expression of BCL2 relative to vector control, confirming that the intrinsic apoptotic pathway was activated by the drug combination (Fig. 2f).

We next assessed whether the everolimus and JQ1 combination activates the extrinsic apoptotic pathway. As shown in Figure 2g, cisplatin, but not JQ1 or its combination with everolimus, induced cleaved caspase 8 in COR-L279 cells. As expected, t-BID was elevated in cells treated by cisplatin but not in those that received JQ1 or the drug combo (Fig. 2h). Taken together, these results demonstrate that the mTORi and BETi combination induces apoptosis by activating the intrinsic apoptotic pathway in SCLC.

mTOR inhibition enhances the antitumor effects of BETi *in vivo* by increasing apoptosis.

To evaluate the antitumor effects of the mTORi and BETi combo *in vivo*, we tested the combination of everolimus and NHWD870 in the SCLC PDX model LX33. As shown in Figure

3a-b, compared to either single drug, concurrent administration of everolimus and NHWD870 resulted in significantly better control of tumor growth and a longer median overall survival (50 days in the combo group versus 30 days in single-agent groups). In another SCLC PDX model (LX95), we tested the combination of everolimus and AZD5153, a bivalent BETi in phase I/II clinical trials (32). Like the combination of everolimus and NHWD870 in LX33, concurrent administration of everolimus and AZD5153 achieved significantly better control of tumor growth and increased the median overall survival from 30 days in single-drug groups to 60 days (Fig. 3c-d). Both drug combinations were reasonably tolerated, except for mild diarrhea or weight loss in a few animals. These side effects commonly improved spontaneously after holding the treatments for a few days.

We also evaluated the combination of AKT inhibitor (AKTi) and BETi *in vivo*. Compared to single-agent AZD5153, the combination of AZD5363 (AKTi) and AZD5153 did not lead to better control of tumor growth or a longer median overall survival in the LX95 model (Fig. S2a-b). The lack of improvement was due to excessive toxicity, as this combination caused severe weight loss, diarrhea, and premature death, none of which occurred in single-agent groups. Despite a 40% dose-reduction of AZD5363, this combination was still difficult to tolerate and necessitated extended treatment delays.

We next assessed whether the combination of mTORi and BETi induced apoptosis *in vivo*. To this end, we measured the expression of cleaved caspase 3 in LX95 tumors after one-week treatment of everolimus and NHWD870. Consistent with our *in vitro* findings, tumor cells positive for cleaved caspase 3 were more commonly present in the xenografts from the drug combo group relative to those in the single-agent groups (Fig. 3e). We next used a tumor cell line established from the LX95 PDX to evaluate whether the drug treatments activated the intrinsic apoptotic

pathway. We first confirmed this cell line formed similar xenograft tumors as those grown from the implanted LX95 tumor blocks (Fig. S3a). Like COR-L279, the combination of everolimus and JQ1 activated the intrinsic apoptotic pathway by increasing cleavage of caspase 9 and release of cytochrome c from mitochondria (Fig. S3b-c). We next examined the role of the extrinsic apoptotic pathway. In agreement with a previous report that this gene is frequently lost in SCLC (33), caspase 8 was barely detectable in LX95 cells (Fig. S3d). Taken together, these results demonstrate that mTORi, but not AKTi, potentiates the antitumor effects of BETi *in vivo* by increasing apoptosis via the intrinsic apoptotic cascade.

BETi upregulates RSK3, a potential upstream kinase of the TSC2-mTOR cascade, in SCLC.

It was previously reported that BETi synergizes with mTORi in breast and colon cancer cell lines by blocking the mTORi-induced RTK feedback activation (15,16). To determine whether this mechanism explains the synergy of the mTORi and BETi combo in SCLC, we compared the changes in AKT T308 phosphorylation following mTOR inhibition between a breast cancer cell line MDA-MB-468 and two SCLC cell lines, COR-L279 and LX95. As shown in Figure S4a-c, a steady increase in AKT T308 phosphorylation following mTOR inhibition, indicative of RTK feedback activation (13-16), was observed only in MDA-MB-468 cells but not in COR-L279 and LX95 cells. These findings suggest that, in SCLC, mTOR inhibition does not induce RTK feedback activation and a different mechanism is responsible for the synergy between mTORi and BETi.

To identify the underlying mechanism of drug synergy, we performed RNA sequencing to profile LX95 PDXs following one-week treatment with everolimus, NHWD870, or their combination. Principal-component analysis showed that the transcriptomes of the tumor cells were

clustered into four treatment groups (Fig. 4a). By comparing the NHWD870-treated tumors to control tumors, a total of 929 genes had at least a 2-fold change in expression with an adjusted P-value less than 0.05. Ingenuity Pathway Analysis of these identified genes correctly predicted that BRD4 was inactivated by NHWD870 treatment, while TSC2, an upstream regulator of mTOR signaling, was among the top activated regulators (Fig. 4b). Interestingly, one of the 20 most upregulated genes in the NHWD870 and combo groups was *RPS6KA2* (Fig. 4c), which belongs to the same family of *RPS6KA1* – a known upstream kinase of TSC2 (34). Using quantitative RT-PCR and immunohistochemical staining, we confirmed that *RPS6KA2* and its encoded protein - RSK3, were induced by NHWD870 or the combo in LX95 tumors (Fig. 4d-e).

We modeled the *in vivo* experiment by treating COR-L279 cells with various doses of JQ1 for one week *in vitro*. JQ1 was confirmed to upregulate the gene and protein expression of RSK3 in the dose range of 12.5 to 50nM (Fig. 4f-g). Collectively, these results demonstrate that BETi induces RSK3, a potential upstream kinase of TSC2, in SCLC.

RSK3 induction increases resistance to BETi-induced apoptosis.

To evaluate the functional consequence of RSK3 induction, we overexpressed a myristoylated (myr) RSK3 in COR-L279 cells. The addition of a myr sequence recruits overexpressed RSK3 to the cell membrane and subsequent activation of its kinase activity (21). Compared to empty vector control, forced expression of myr-RSK3 increased phosphorylation at TSC2 S1798, demonstrating that TSC2 is a kinase substrate of RSK3 (Fig. 5a). Phosphorylation at p70S6K1 T389, a direct downstream target of mTORC1, was also increased in the RSK3-overexpressed cells, indicating that RSK3 augments mTOR signaling (Fig. 5a). To determine whether BETi-induced RSK3 could activate the TSC2-mTOR-p70S6K1 signaling, we treated

COR-L279 cells with JQ1 at 50nM for one week. As shown in Figure 5b, a similar increase in phosphorylation at both TSC2 S1798 and p70S6K1 T389 was observed, demonstrating that BETi activates TSC2-mTOR signaling via RSK3 upregulation.

To evaluate how RSK3 upregulation would affect cell response to BETi, we first used LJH685, a selective inhibitor of the RSK family kinases (35), to block TSC2 phosphorylation by RSK kinases (Fig. 5c). Figure 5d shows that LJH685 enhanced caspase 3/7 activation following JQ1 treatment in COR-L279 cells. Next, we overexpressed myr-RSK3 in COR-L279 cells and observed a decrease in JQ1-induced caspase 9 and PARP cleavage, suggesting that RSK3 induction attenuates JQ1-induced apoptosis (Fig. 5e). Everolimus abrogated the protective effect of RSK3 overexpression, as the combo induced the same levels of cleaved caspase 9 and PARP in RSK3-overexpressed cells compared to control cells (Fig. 5e). Collectively, these findings demonstrate that BETi-induced RSK3 activates TSC2-mTOR signaling and causes resistance to BETi-induced apoptosis; and mTORi abolishes this protective effect.

p70S6K1 mediates the antiapoptotic effects of RSK3 by phosphorylating BAD

To determine whether p70S6K1 mediates the antiapoptotic effects of RSK3, we treated COR-L279 cells with JQ1 with or without PF-4708671, a specific inhibitor of p70S6K1. As shown in Fig. 6a, the combination of PF-4708671 and JQ1 recapitulated the increased apoptosis caused by the mTORi and BETi combination. To further define the role of p70S6K1, we overexpressed a constitutively active form of rat S6K1 (S6K1-deltaCT) and the wildtype (S6K1-WT) in COR-L279 cells. As shown in Figure 6b-c, S6K1-deltaCT, but not S6K1-WT, increased the viability and decreased apoptosis after JQ1 treatment, confirming that p70S6K1 mediates the antiapoptotic effects of RSK3.

To identify the downstream effector of p70S6K1, we examined phosphorylation of the proapoptotic protein BAD, a known substrate of p70S6K1 (36). Phosphorylation of BAD releases antiapoptotic proteins BCL-2 and BCL-xl and promotes survival (37). After one-week treatment of JQ1, phosphorylation at BAD S112, but not at S136 and S155, increased in COR-L279 cells (Fig. 6d). A similar increase in BAD phosphorylation was observed after overexpression of RSK3 or S6K1-deltaCT in HEK293T cells, suggesting that RSK3 increases BAD phosphorylation via p70S6K1 (Fig. 6e).

We next assessed whether autophagy - a downstream pathway suppressed by mTOR, is involved in the synergy between mTORi and BETi. LC3B-II, a marker of autophagosome formation (38), was modestly induced by everolimus, consistent with autophagy induction after mTOR inhibition (Fig. S5). JQ1 did not induce LC3B-II, and neither did it affect everolimus-induced LC3B-II, suggesting that altered autophagy is not responsible for the synergy between mTORi and BETi (Fig. S5). Taken together, our findings support a model that RSK3 increases BAD phosphorylation via the TSC2-mTOR-p70S6K1 signaling cascade, and mTORi blocks this signaling and potentiates BETi-induced apoptosis (Fig. 6f).

Discussion

Multiple investigational BETi drugs have been evaluated in early-phase clinical trials, and the results generally showed modest response rates and a short duration of response (39). Rational drug combinations could increase the antitumor efficacy of BETi and delay the development of drug resistance (39). In this study, we demonstrate that mTORi potentiates the antitumor effects of BETi in SCLC. RSK3 induction was identified as a resistance mechanism to BETi, and mTORi blocks the downstream signaling of this kinase and enhances BETi-induced apoptosis in SCLC.

Using high-throughput combination screens, we identified several classes of drugs synergizing with BETi in an unbiased manner. Some of these candidates, such as BCL2 inhibitors and HDAC inhibitors, have been shown previously to potentiate the antitumor effects of BETi in SCLC (7,10), while several others, such as inhibitors of cyclin-dependent kinases and carfilzomib, were reported to synergize with BETi in other tumor types (40,41). These earlier studies indirectly validate our results, suggesting shared vulnerabilities between various tumor types.

We focused on the combination of mTORi and BETi for further validation and mechanistic studies. Our results demonstrate that this combination has better antitumor effects than the single agents *in vitro* and *in vivo*. In addition, this combo was relatively well-tolerated, likely because the adverse effects of mTORi and BETi affect different organ systems. In contrast, the AKTi and BETi combo had poor tolerability *in vivo* despite being synergistic *in vitro*, probably because of overlapping adverse effects (e.g., diarrhea) of AKTi and BETi (42,43). These results stress the need to select the drugs with non-overlapping toxicities to increase antitumor activity and minimize adverse effects.

Unlike the findings in previous studies (13,15,16), our results did not support the feedback activation of RTKs after mTOR inhibition in SCLC. Previous studies have indicated epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor (IGF-1R) signaling pathways are commonly involved in the feedback activation of RTKs (14,16). In SCLC, EGFR signaling is inactive, while IGF-1R is upregulated in about 18.5% of the primary tumors (44). We suspect that the suppression of EGFR signaling accounts for the lack of feedback activation of RTKs following mTOR inhibition in SCLC.

Our study revealed *RPS6KA2* induction as a novel resistance mechanism to BETi in SCLC. The pro-survival function of RSK3 is mediated through mTOR signaling, which explains why

mTORi would potentiate the antitumor effects of BETi. In breast and ovarian cancers, a higher expression of *RPS6KA2* has been associated with a worse prognosis, suggesting that this gene functions as an oncogene (45,46). Besides TSC2, RSK3 can also phosphorylate I κ B α and causes activation of NF- κ B (46). Previous studies in other neoplasms have reported that BETi resistance is caused by upregulation of WNT signaling via transcriptional program reset (47) or an increase of PI-3K-ERK activity through RTKs kinome rewiring (48). Our findings reveal a new player in the already diverse mechanisms of BETi resistance and confirm the central role of PI-3K-AKT-mTOR signaling activation.

In conclusion, we demonstrate that mTORi potentiates the antitumor effects of BETi in SCLC by blocking an RSK3-mediated survival signaling cascade. Our findings warrant further evaluation of mTORi and BETi combinations in SCLC patients.

References

1. National Cancer Institute. Scientific Framework for Small Cell Lung Cancer (SCLC). *Scientific Framework for Small Cell Lung Cancer (SCLC)*. URL <https://deainfo.nci.nih.gov/advisory/ctac/workgroup/SCLC/SCLC%20Congressional%20Response.pdf> Last visited: 10-12-2021.
2. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, *et al*. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. *N Engl J Med* 2020;**383**:640-9.
3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Small Cell Lung Cancer. V3.2021. URL https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Last visited: 10-12-2021.
4. Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. *Mol Cell* 2014;**54**:728-36.
5. Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, *et al*. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. *Cancer Cell* 2014;**26**:909-22.
6. Lenhart R, Kirov S, Desilva H, Cao J, Lei M, Johnston K, *et al*. Sensitivity of small cell lung cancer to BET inhibition is mediated by regulation of ASCL1 gene expression. *Mol Cancer Ther* 2015;**14**:2167-74.
7. Lam LT, Lin X, Faivre EJ, Yang Z, Huang X, Wilcox DM, *et al*. Vulnerability of small-cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors. *Mol Cancer Ther* 2017;**16**:1511-20.

8. Fiorentino FP, Marchesi I, Schröder C, Schmidt R, Yokota J, Bagella L. BET-inhibitor I-BET762 and PARP-inhibitor talazoparib synergy in small cell lung cancer cells. *Int J Mol Sci* 2020; **21**:9595.
9. Wang H, Hong B, Li X, Deng K, Li H, Yan Lui VW, *et al.* JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer. *Oncotarget* 2017; **8**:86312-24.
10. Liu Y, Li Y, Liu S, Adeegbe DO, Christensen CL, Quinn MM, *et al.* NK Cells mediate synergistic antitumor effects of combined inhibition of HDAC6 and BET in a SCLC preclinical model. *Cancer Res* 2018; **78**:3709-17.
11. Kern JA, Kim J, Foster DG, Mishra R, Gardner EE, Poirier JT, *et al.* Role of mTOR As an Essential Kinase in SCLC. *J Thorac Oncol* 2020; **15**:1522-34.
12. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, *et al.* Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. *Clin Cancer Res* 2010; **16**:5900-7.
13. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, *et al.* mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. *Cancer Discov* 2011; **1**:248-59.
14. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, *et al.* mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res* 2006; **66**:1500-8.
15. Lee HS, Lee S, Cho KH. Cotargeting BET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer. *Int J Cancer* 2020; **147**:2824-37.

16. Stratikopoulos EE, Dendy M, Szabolcs M, Khaykin AJ, Lefebvre C, Zhou MM, *et al.* Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. *Cancer Cell* 2015;**27**:837-51.
17. Wang NS, Unkila MT, Reineks EZ, Distelhorst CW. Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death. *J Biol Chem* 2001;**276**:44117-28
18. Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, *et al.* High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. *Proc Natl Acad Sci USA* 2014;**111**:2349-54.
19. Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H. A new Bliss independence model to analyze drug combination data. *J Biomol Screen* 2014;**19**:817-21.
20. Lehár J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, *et al.* Chemical combination effects predict connectivity in biological systems. *Mol Syst Biol* 2007;**3**:80.
21. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, *et al.* Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene. *Cell* 2007;**129**:1065-79.
22. Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, *et al.* Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. *Cancer Cell* 2017;**31**:286-99.

23. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, *et al.* Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. *Cancer Res* 2008;**68**:2321-8.
24. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, *et al.* QuPath: Open source software for digital pathology image analysis. *Sci Rep* 2017;**7**:16878.
25. Schneeberger VE, Allaj V, Gardner EE, Poirier JT, Rudin CM. Quantitation of murine stroma and selective purification of the human tumor component of patient-derived xenografts for genomic analysis. *PLoS ONE* 2016;**11**:e0160587.
26. Köster J, Rahmann S. Snakemake—a scalable bioinformatics workflow engine. *Bioinformatics* 2012;**28**:2520-2.
27. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, *et al.* Orchestrating high-throughput genomic analysis with Bioconductor. *Nat Methods* 2015;**12**:115-21.
28. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;**15**:550.
29. Zhu A, Ibrahim JG, Love MI. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. *Bioinformatics* 2019;**35**:2084-92.
30. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv Enzym Regul* 1984;**22**:27-55.
31. Yin M, Guo Y, Hu R, Cai WL, Li Y, Pei S, *et al.* Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. *Nat Commun* 2020;**11**:1833.
32. Waring MJ, Chen H, Rabow AA, Walker G, Bobby R, Boiko S, *et al.* Potent and selective bivalent inhibitors of BET bromodomains. *Nat Chem Biol* 2016;**12**:1097-104.

33. Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, *et al.* Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. *Cell Death Differ* 2003;**10**:356-64.
34. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. *Cell* 2005;**121**:179-93.
35. Aronchik I, Appleton BA, Basham SE, Crawford K, Del Rosario M, Doyle LV, *et al.* Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers. *Mol Cancer Res* 2014;**12**:803-12.
36. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. *Proc Natl Acad Sci USA* 2001;**98**:9666-70.
37. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). *Cell* 1996;**87**:619-28.
38. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, *et al.* LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *EMBO J* 2000;**19**:5720-8.
39. Cochran AG, Conery AR, Sims RJ. Bromodomains: a new target class for drug development. *Nat Rev Drug Discov* 2019;**18**:609-28.
40. Vangala JR, Potluri A, Radhakrishnan SK. BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response. *Biomolecules* 2020;**10**:501.

41. Bolin S, Borgenvik A, Persson CU, Sundström A, Qi J, Bradner JE, *et al.* Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. *Oncogene* 2018;**37**:2850-62.
42. Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, *et al.* A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. *Clin Cancer Res* 2018;**24**:2050-9.
43. Wang JS-Z, Vita SD, Karlix JL, Cook C, Littlewood GM, Hattersley MM, *et al.* First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data. *J Clin Oncol* 2019;**37**:3085-3085.
44. Badzio A, Wynes MW, Dziadziuszko R, Merrick DT, Pardo M, Rzyman W, *et al.* Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer. *J Thorac Oncol* 2010;**5**:1905-11.
45. Zafar A, Wu F, Hardy K, Li J, Tu WJ, McCuaig R, *et al.* Chromatinized protein kinase C- θ directly regulates inducible genes in epithelial to mesenchymal transition and breast cancer stem cells. *Mol Cell Biol* 2014;**34**:2961-80.
46. Yoon HS, Choi SH, Park JH, Min JY, Hyon JY, Yang Y, *et al.* A novel protein-protein interaction between RSK3 and I κ B α and a new binding inhibitor that suppresses breast cancer tumorigenesis. *Cancers* 2021;**13**:2973.
47. Rathert P, Roth M, Neumann T, Muerdter F, Roe J-S, Muhar M, *et al.* Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. *Nature* 2015;**525**:543-7.

48. Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, *et al.* Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. *Cell Rep* 2016;**16**:1273-86.

Authors' Contributions

A. Kumari: Investigation, validation, methodology, writing–review and editing. **L. Gesumaria:** Investigation, validation, methodology, writing–review and editing. **Y. Liu:** Investigation, writing–review and editing. **VK Hughitt:** software, data curation, formal analysis, writing–review and editing. **X Zhang, M. Ceribelli, KM Wilson, C. Klump-Thomas, L. Chen, C. McKnight, Z. Itkin:** Investigation, software, data curation, formal analysis. **CJ Thomas:** Resources, formal analysis, funding acquisition, investigation, visualization, methodology, writing–review and editing. **BA Mock:** Conceptualization, funding acquisition, data curation, software, formal analysis, writing–review and editing. **DS Schrump:** Conceptualization, resources, funding acquisition, writing–review and editing. **H Chen:** Conceptualization, methodology, formal analysis, investigation, data curation, writing–original draft, writing–review and editing, visualization, supervision, project administration, funding acquisition.

Acknowledgments

The authors thank Drs. Yulong Li, Shih-Hsin Hsiao, Kaitlin C. McLoughlin, Sichuan Xi, Ruihong Wang, Yuan Xu, Patricia Fetsch, and Markku M. Miettinen for their assistance in this study; Drs. Charles Rudin and John T. Poirier for providing the SCLC PDX models; Drs. Nenghui Wang and Mingzhu Yin for providing NHWD870.

Figures

Figure 1. mTORi synergizes with BETi *in vitro*. (a) Ranking of synergy and antagonism of JQ1 in combination with 1,912 agents in the MIPE (Mechanism of Interrogation Plate) 4.0 library, according to the Excess HSA (Highest Single Agency) metric in the primary screens in H446 cells. Prominent drug synergies are shown, including the combination of JQ1 with several mTORi agents. (b) The percentage response (top) and Δ Bliss (bottom) heatmaps for the 10 X 10 screen of the JQ1 and everolimus combination in H446 cells. (c) The candidates that synergized with BETi in at least three SCLC lines in the 10 X 10 screens. A, B, C, and D represent inhibitors targeting the PI-3K-AKT-mTOR pathway, cyclin-dependent kinases, proteolysis, and HDAC, respectively. (d) Relative viability of COR-L279 cells at the 72-hour time interval after treatment of JQ1, rapamycin, or their combination. (e) Synergy plot showing the combination index (CI) versus affected fractions calculated based on the viability results of the specified drug-drug combinations in COR-L279 cells at the 72-hour time interval.

Figure 2. mTORi amplifies BETi-induced apoptosis in SCLC via the intrinsic apoptotic cascade. (a) Relative viability of COR-L279 cells at 72 hours after treatment with the JQ1 and rapamycin combo with or without a pan-caspase inhibitor, Z-VAD-FMK (2.5μM). (b) A diagram illustrating the intrinsic and extrinsic apoptotic cascades. (c) Western blots show caspase 9, caspase 3, and PARP cleavage in COR-L279 cells at 24 hours following treatment of JQ1 (1μM), everolimus (6.25nM), or their combination. (d) Western blots show cytochrome c abundance in mitochondria and cytoplasmic fractions of COR-L279 cells, at 16 hours after treatment of JQ1 (1μM), everolimus (6.25nM), or their combination. Actinomycin D (1μg/ml, 16 hours) was used as a positive control. β-actin and Cox IV serve as loading controls for the cytoplasmic and mitochondrial fractions, respectively. (e) Ectopic expression of BCL2 in H446 cells as assessed by immunoblotting. (f) Relative viability of H446 cells with ectopic expression of BCL2 versus control cells at 72 hours after treatment of JQ1, rapamycin, or the combination. (g-h) Western blots show cleaved caspase 8 (g) and t-BID (h) in COR-L279 cells following treatment of JQ1 (1μM), everolimus (6.25nM), or the combination. Cisplatin at 20μM and 50μM were used as positive controls in (g) and (h), respectively. The significance of the two-group comparisons was determined using the Student's *t*-test in (a) and (f). Error bars represent SD; **, *p*<0.01; ***, *p*<0.001; ****, *P*<0.0001. OE, overexpression.

Figure 3. mTOR inhibition enhances the antitumor effects of BETi *in vivo* by increasing apoptosis. (a-b) Compared to either single agent, the combination of everolimus (3mg/kg, daily) and NHWD870 (3mg/kg, daily) was more effective in controlling tumor growth (a) and prolonging survival (b) in the LX33 SCLC PDX model ($n \geq 10$ per group). **(c-d)** Compared to single-agent everolimus (2mg/kg, daily) and AZD5153 (1.5 mg/kg, daily), concurrent treatment with both drugs at 1mg/kg daily was more effective in controlling tumor growth (c) and prolonging survival (d) in the LX95 model ($n=9$ per group). **(e)** Representative images (left) and quantification (right) of cleaved caspase 3 IHC staining in LX95 PDX tumors after one-week treatment of everolimus (2mg/kg, daily), NHWD870 (1.5mg/kg, daily), or the combination (everolimus 1.5mg/kg and NHWD870 1mg/kg, daily). $n=7$ per group. Horizontal lines in the right panel represent medians. The significance of the two-group comparisons was determined using the Student's *t*-test in (a) and (c) and Log-rank test in (b) and (d). Statistically significant differences in tumor volumes between the BETi single-agent and vehicle groups are indicated with black asterisks, while those between the combo and BETi single-agent groups are marked with red asterisks. Error bars represent SD; *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$. A, AZD5153; E, everolimus; N, NHWD870; V, vehicle; CC3, cleaved caspase 3; IHC, immunohistochemical staining.

Figure 4. BETi upregulates *RPS6KA2* and its encoded protein RSK3 in SCLC *in vitro* and *in vivo*. (a) Principal Component Analysis plot showing clustering of LX95 PDXs treated with everolimus (2mg/kg, daily), NHWD870 (1.5mg/kg, daily), the combination (everolimus 1.5mg/kg and NHWD870 1mg/kg, daily), or vehicle (daily) for one week. (b) The volcano plot for the statistical significance (Y-axis) versus the degree of activation or inhibition (X-axis) of the upstream regulators predicted by Ingenuity Pathway Analysis. The input data was the differentially expressed genes (>2 fold-change and adjusted p-value <0.05) comparing the tumors in the NHWD870 group vs. control tumors. (c) Heatmap of the top 20 up- and down-regulated genes in the combo group relative to the vehicle group. The arrowhead points to the heatmap of *RPS6KA2*. (d-e) qRT-PCR and IHC staining assessing RSK3 gene and protein expression in the LX95 PDX tumors treated with vehicle, NHWD870, everolimus, or the combo. (f-g) RSK3 gene and protein expression in COR-L279 cells following one-week treatment of JQ1 at 50nM (f) or the specified doses (g). Fresh media and JQ1 were replenished every three days. The significance of the two-group comparisons was determined using the Student's *t*-test in (f) and the ANOVA test with multiple comparison correction in (d). Error bars represent SD; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

Figure 5. RSK3 upregulation causes resistance to BETi-induced apoptosis. (a) Phosphorylation at TSC2 S1798 and p70S6K1 T389 in COR-L279 cells after forced expression of myr-RSK3 versus empty vectors (EV). NaK-ATPase was used as a loading control for membrane fraction proteins. (b) Phosphorylation status at TSC2 S1798 and p70S6K1 T389 in COR-L279 cells treated with JQ1 (50 nM, 7 days) versus control cells. (c) Reduction of phosphorylation at TSC2 S1798 following 24-hour treatment of LJH685 at 5, 10, 20 μ M. (d) LJH685 (10 μ M) enhanced JQ1-induced caspase 3/7 activation in COR-L279 cells at 48 hours post-treatment. (e) Overexpression of myr-RSK3 attenuated apoptosis caused by JQ1 but not by the combo. One day after transfection with Myr-RSK3 expression vector or empty vector (EV), COR-L279 cells were treated with JQ1 (1 μ M), everolimus (10 nM), or the combination for 24 hours before cleaved PARP and caspase 9 were assessed by immunoblotting. The significance of the two-group comparisons was determined using the Student's *t*-test in (d). The error bars represent SD; ****, $P < 0.0001$.

Figure 6. p70S6K1 mediates the antiapoptotic effects of BETi-induced RSK3. (a) Cleavage of caspase 3 in COR-L279 cells at 24 hours after treatment of JQ1 (1.67 μ M), PF-4708671 (PF; 16 μ M), their combination. Etoposide serves as a positive control. (b-c) Overexpression of an active form of S6K1 (HA-tagged S6K1-deltaCT), but not the wildtype (HA-tagged S6K1-WT), attenuated the JQ1-induced growth inhibition and apoptosis in COR-L279 cells. Two days after transfection, JQ1 was administered at the specified doses for 72 hours (b) or at 1 μ M for 24 hours (c). Error bar represents SD. (d) Western blots show changes in BAD phosphorylation at S112, S136, and S155 after JQ1 treatment for 7 days at the specified doses. (e) Effects of RSK3 and S6K1-deltaCT overexpression on BAD phosphorylation two days after transfection in HEK293T cells. (f) A proposed model shows that BETi induces RSK3, which activates the TSC2-mTOR-p70S6K-BAD pathway to increase cell survival; mTOR inhibitor blocks this survival cascade and enhances BETi-induced apoptosis.

Supplemental Materials

Figure S1: mTORi synergizes with BETi *in vitro*.

Figure S2. Compared to the single agents, the combination of AZD5363 (AKTi) and AZD5153 (BETi) failed to improve tumor control and survival in the LX95 PDX model.

Figure S3. Everolimus enhances JQ1-induced apoptosis in LX95 cells via the intrinsic apoptotic cascade.

Figure S4. mTOR inhibition does not cause RTK feedback activation in SCLC.

Figure S5. JQ1 does not affect everolimus-induced autophagy in COR-L279 cells.

Table S1. The list of the antibodies and their dilutions used in this study.

Table S2. The results of the first high-throughput combination screens in H446 cells.

Table S3. The list of differential expression genes comparing the LX95 PDX tumors in the NHWD870, everolimus, or the combination groups to those in the vehicle group.

a

b

c

Figure S1. mTORi synergizes with BETi *in vitro*. (a) Synergy plots showing CIs versus affected fractions in H446 (left) or H187 cells (right) at 72 hours following treatment with JQ1 in combination with copanlisib, MK2206, or rapamycin. (b) Synergy plots showing CIs versus affected fractions in COR-L279 cells at 72 hours following treatment with various mTORi and BETi combinations as specified. (c) Synergy plot showing CIs versus affected fractions in three BETi-resistant SCLC lines (COR-L88, H1436, and H1048) at 72 hours following treatment with JQ1 in combination with everolimus.

Figure S2. Compared to the single agents, the combination of AZD5363 (AKTi) and AZD5153 (BETi) failed to improve tumor control and survival in the LX95 PDX model. (a) Relative tumor volume changes in the first 29 days after drug administration. **(b)** Kaplan-Meier survival curves. LX95 PDX mice were initially treated with single-agent AZD5153 (1.5mg/kg, daily), single-agent AZD5363 (50mg/kg, daily), or the combination (AZD5153 1 mg/kg and AZD5363 50mg/kg, daily). Due to premature deaths in the combo group, the dose of AZD5363 in the combination group was reduced to 30mg/kg two weeks after the first dose. Black asterisks indicate statistically significant differences in tumor volumes between the AZD5153 single-agent group and Vehicle group, as determined by the Student's *t*-test. No significant difference was found when comparing tumor volumes between the combo group and the AZD5153 single-agent group. The significance of the two-group comparisons in (b) was determined by the Log-rank test. Error bars represent SD. Where indicated, *, $p < 0.05$; ***, $p < 0.001$; ****, $p < 0.0001$.

Figure S3. Everolimus enhances JQ1-induced apoptosis in LX95 cells via the intrinsic apoptotic cascade. (a) Hematoxylin and eosin staining of the xenograft tumors formed by an implanted LX95 PDX tumor block (left) or the LX95-derived cell line (right). **(b)** Western blots show cleavage of caspase 9, caspase 3, or PARP in LX95 cells at 16, 24, and 30 hours after treatment with JQ1 (156nM), everolimus (6.25nM), or the combination. **(c)** Western blots show cytochrome c abundance in the mitochondria and cytoplasmic fractions of LX95 cells at 16 hours after treatment with JQ1 (1 μ M), everolimus (6.25nM), or their combination. Actinomycin D (1 μ g/ml, 16 hours) was used as a positive control. **(d)** Western blots showing expression of caspase 8 in two non-small cell lung cancer lines (H460 and Calu-6) and two SCLC lines (COR-L279 and LX95).

Figure S4. mTOR inhibition does not cause RTK feedback activation in SCLC. (a) Western blots show the dynamic changes of AKT T308 phosphorylation after everolimus treatment (5nM) in COR-L279 (left) or LX95 cells (middle), or after AZD8055 treatment (500nM) in COR-L279 cells (right). Phosphorylation of S6 S240/244 was examined to ensure mTOR inhibition after drug treatments. **(b)** Western blots show the dynamic changes of AKT T308 phosphorylation in MDA-MB-468 cells after treatment with everolimus (5nM), copanlisib (1μM), and AZD8055 (500nM). Copanlisib was used as a positive control. **(c)** Densitometry of AKT T308 phosphorylation in (a-b). AZD, AZD8055; Copa, copanlisib; Ever, everolimus.

Figure S5. JQ1 does not affect everolimus-induced autophagy in COR-L279 cells. COR-L279 cells were treated with JQ1 (1 μ M), everolimus (6.25nM), or the combination for 24 hours before immunoblotting for LC3B-I and LC3B-II expression. Chloroquine (200 μ M, 24 hours) and bafilomycin (150 nM, 24 hours) were used as positive controls.

Table S1. The list of the antibodies used in this study.

Antibody target	Vendor and catalog number	Dilution
β -actin	Santa Cruz Biotechnology, #sc-47778	1:2,000
AKT	Cell Signaling Technology, #2920	1:1,000
Phos-AKT T308	Cell Signaling Technology, #4056	1:1,000
BAD	Cell Signaling Technology, #9239	1:1,000
Phos-BAD S112	Cell Signaling Technology, #5284	1:1,000
Phos-BAD S136	Cell Signaling Technology, #4366	1:1,000
Phos-BAD S155	Cell Signaling Technology, #9297	1:1,000
BID	Cell Signaling Technology, #2002	1:1,000
BCL2	Cell Signaling Technology, #2876	1:1,000
Cleaved caspase 3	Cell Signaling Technology, #9661	1:1,000
Caspase 3	Cell Signaling Technology, #9662	1:1,000
Cleaved caspase 8	Cell Signaling Technology, #9496	1:1,000
Caspase 8	Cell Signaling Technology, #4790	1:1,000
Cleaved caspase 9	Cell Signaling Technology, #7237	1:1,000
Caspase 9	Cell Signaling Technology, #9502	1:1,000
Cleaved caspase 3	Cell Signaling Technology, #9661	1:1,000
Caspase 3	Cell Signaling Technology, #9662	1:1,000
Cleaved PARP	Cell Signaling Technology, #9542	1:1,000
PARP	Cell Signaling Technology, #9662	1:1,000
COX IV	Cell Signaling Technology, #4850	1:1,000
Cytochrome C	Abcam, #Ab110325	1:2,000
HA-tag	Cell Signaling Technology, #3724	1:1,000
LC-3B	Cell Signaling Technology, #3868	1:1,000
NaK-ATPase	Santa Cruz Biotechnology, #sc-71638	1:1,000
p70S6K1	Cell Signaling Technology, #9202	1:1,000
Phos-p70S6K1 T389	Cell Signaling Technology, #9205	1:1,000
RSK3	Novus Biologicals, #NBP2-52555	1:1,000
Phos-TSC Ser1798	Santa Cruz Biotechnology, #sc-293149	1:1,000
phos-S6 S240/244	Cell Signaling Technology, #5364	1:1,000
TSC2	Cell Signaling Technology, #4308	1:1,000
γ -tubulin	Sigma, #T6557	1:10,000
γ -tubulin	Abcam, #Ab11316	1:5,000